Compare Stocks: NIO, TWLO, and CRSP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$53.39	$55.14	$44.12 ▼ $78.00	$5.16B	1.76	1.86 million shs	1.47 million shs
NIO NIO	$3.59 +0.1%	$4.01	$3.36 ▼ $7.54	$8.90B	0.92	30.83 million shs	43.82 million shs
TWLO Twilio	$289.46 0.0%	$246.99	$104.50 ▼ $308.40	$44.45B	1.35	4.66 million shs	2.62 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-3.68%	+3.23%	+5.45%	-26.93%
NIO NIO	0.00%	+6.22%	-2.71%	-27.36%	-46.65%
TWLO Twilio	0.00%	-1.96%	+27.34%	+32.68%	+169.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$53.39	$55.14	$44.12 ▼ $78.00	$5.16B	1.76	1.86 million shs	1.47 million shs
NIO NIO	$3.59 +0.1%	$4.01	$3.36 ▼ $7.54	$8.90B	0.92	30.83 million shs	43.82 million shs
TWLO Twilio	$289.46 0.0%	$246.99	$104.50 ▼ $308.40	$44.45B	1.35	4.66 million shs	2.62 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-3.68%	+3.23%	+5.45%	-26.93%
NIO NIO	0.00%	+6.22%	-2.71%	-27.36%	-46.65%
TWLO Twilio	0.00%	-1.96%	+27.34%	+32.68%	+169.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.68	Moderate Buy	$67.94	27.25% Upside
NIO NIO	2.27	Hold	$5.87	63.64% Upside
TWLO Twilio	2.86	Moderate Buy	$258.65	-10.64% Downside

Current Analyst Ratings Breakdown

Latest NIO, TWLO, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/9/2026	CRSP CRISPR Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/8/2026	TWLO Twilio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$260.00 ➝ $335.00
9/29/2026	TWLO Twilio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/24/2026	TWLO Twilio	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Reduce	$211.00
9/23/2026	CRSP CRISPR Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	TWLO Twilio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $300.00
9/22/2026	TWLO Twilio	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$275.00 ➝ $290.00
9/11/2026	TWLO Twilio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$285.00
9/7/2026	TWLO Twilio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$11M	469.31	N/A	N/A	$20.17 per share	2.65
NIO NIO	$12.51B	0.71	N/A	N/A	$0.24 per share	14.94
TWLO Twilio	$5.57B	7.98	$6.50 per share	44.51	$51.32 per share	5.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
NIO NIO	-$2.14B	-$0.27	N/A	71.70	N/A	-3.95%	-111.37%	-3.62%	11/24/2026 (Estimated)
TWLO Twilio	$33.83M	$7.18	40.31	72.91	5.94	20.61%	5.09%	4.15%	10/29/2026 (Estimated)

Latest NIO, TWLO, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	N/A	CRSP CRISPR Therapeutics	-$1.04	N/A	N/A	N/A	$14.62 million	N/A
10/29/2026	Q3 2026	TWLO Twilio	$1.47	N/A	N/A	N/A	$1.52 billion	N/A
9/1/2026	Q2 2026	NIO NIO	-$0.07	$0.0010	+$0.0710	-$0.04	$4.79 billion	$4.73 billion
8/15/2026	Q2 2026	NIO NIO	N/A	$0.0010	N/A	-$0.04	N/A	$4.73 billion
8/6/2026	Q2 2026	TWLO Twilio	$1.32	$1.47	+$0.15	$6.68	$1.43 billion	$1.50 billion
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NIO NIO	N/A	N/A	N/A	N/A	N/A
TWLO Twilio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
NIO NIO	2.11	1.02	0.89
TWLO Twilio	0.11	4.62	4.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
NIO NIO	48.55%
TWLO Twilio	84.27%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
NIO NIO	1.00%
TWLO Twilio	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
NIO NIO	35,032	2.48 billion	2.46 billion	Optionable
TWLO Twilio	5,587	153.58 million	153.25 million	Optionable

NIO, TWLO, and CRSP Headlines

Recent News About These Companies

Twilio (TWLO) Shares Just Moved, So What Is Going On?

October 10 at 10:43 AM | finance.yahoo.com

Twilio (TWLO) Stock Trades Up, Here Is Why

October 10 at 5:42 AM | finance.yahoo.com

Should Twilio’s (TWLO) Inclusion in the S&P 500 Require Action From Existing Investors?

October 10 at 5:42 AM | finance.yahoo.com

Twilio (NYSE:TWLO) Stock Gets Price Target Boost from JPMorgan Chase & Co.

October 10 at 2:13 AM | americanbankingnews.com

Twilio (TWLO) Stock May Be Expensive Following Its 421% 3 Year Run

October 9 at 7:15 PM | finance.yahoo.com

What Is Twilio (TWLO) Telling Investors With Its New Big Cap Index Status?

October 9 at 2:14 PM | finance.yahoo.com

Twilio to Announce Third Quarter 2026 Results on October 29, 2026

October 8, 2026 | finance.yahoo.com

Twilio to Announce Third Quarter 2026 Results on October 29, 2026

October 8, 2026 | businesswire.com

Twilio (NYSE:TWLO) Stock Gets Price Target Bump from JPMorgan Chase & Co.

October 8, 2026 | marketbeat.com

Twilio Inc. $TWLO Stock Bought by Artemis Investment Management LLP

October 8, 2026 | marketbeat.com

Twilio (NYSE:TWLO) CEO Khozema Shipchandler Sells 14,442 Shares of Stock

October 8, 2026 | insidertrades.com

Twilio rally fuels investor concerns ahead of earnings, Jefferies says

October 7, 2026 | msn.com

Twilio shares up 97% this year as investors focus on third-quarter gross profit growth, Jefferies says

October 7, 2026 | proactiveinvestors.com

Twilio (NYSE:TWLO) Stock: Insider Khozema Shipchandler Sells 14,442 Shares

October 7, 2026 | marketbeat.com

Twilio shares up 97% this year as investors focus on third-quarter gross profit growth, Jefferies says

October 7, 2026 | proactiveinvestors.com

39,350 Twilio Inc. $TWLO Shares Bought by Glynn Capital Management LLC

October 7, 2026 | marketbeat.com

Twilio (NYSE:TWLO) Sets New 12-Month High - Here's Why

October 7, 2026 | marketbeat.com

Twilio Inc. $TWLO Shares Bought by Congress Asset Management Co.

October 6, 2026 | marketbeat.com

What's Going On With Twilio Stock Tuesday?

October 6, 2026 | benzinga.com

Eleva Capital SAS Makes New Investment in Twilio Inc. $TWLO

October 6, 2026 | marketbeat.com

Twilio (TWLO) Outperforms Broader Market: What You Need to Know

October 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NIO, TWLO, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$53.39 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$53.68 +0.29 (+0.54%)

As of 10/9/2026 07:57 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

NIO NYSE:NIO

$3.58 +0.01 (+0.14%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$3.58 0.00 (0.00%)

As of 10/9/2026 07:59 PM Eastern

NIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Twilio NYSE:TWLO

$289.46 -0.01 (0.00%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$290.02 +0.57 (+0.20%)

As of 10/9/2026 07:57 PM Eastern

Twilio Inc., together with its subsidiaries, provides customer engagement platform solutions in the United States and internationally. It operates through two segments, Twilio Communications and Twilio Segment. The company provides various application programming interfaces and software solutions for communications between customers and end users, including messaging, voice, email, flex, marketing campaigns, and user identity and authentication. It also offers software products to build direct, personalized relationships with their end users, such as segment, a platform that provides tools for first-party data by unifying real-time information collected; and engage, an automation platform for the delivery of omnichannel campaigns. Twilio Inc. was incorporated in 2008 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NIO, TWLO, and CRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NIO, TWLO, and CRSP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NIO, TWLO, and CRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NIO, TWLO, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

NIO NYSE:NIO

Twilio NYSE:TWLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NIO, TWLO, and CRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NIO, TWLO, and CRSP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NIO, TWLO, and CRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NIO, TWLO, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

NIO NYSE:NIO

Twilio NYSE:TWLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools